MSLN and pancreatic adenocarcinoma: LMB-100 is currently in Phase I/II trials in patients with mesothelioma, cholangiocarcinoma and pancreatic adenocarcinoma; however, the potential of mesothelin-targeted ITX in CRC has been overlooked.